Min Wang

Title: Min Wang: Innovator in Chimeric Antigen Receptor Technology

Introduction

Min Wang is a prominent inventor based in Tianjin, China. He has made significant contributions to the field of immunotherapy, particularly through his work on chimeric antigen receptors (CARs). His innovative approach aims to enhance the efficacy of immune responses against cancer cells.

Latest Patents

Min Wang holds a patent for a CD19-targeted chimeric antigen receptor and its applications. This patent includes a chimeric antigen receptor comprising an amino acid sequence shown in SEQ ID NO. 1. It also covers a nucleic acid encoding the chimeric antigen receptor, a vector comprising the nucleic acid, and an immune effector cell that incorporates the chimeric antigen receptor. The patent outlines methods for preparing the immune effector cell, compositions that include the immune effector cell, and the use of the chimeric antigen receptor in therapeutic applications. He has 1 patent to his name.

Career Highlights

Min Wang is currently associated with Juventas Cell Therapy Ltd., where he continues to advance his research in cell therapy and immunology. His work has positioned him as a key figure in the development of innovative cancer treatments.

Collaborations

Min Wang collaborates with notable colleagues, including Jianxiang Wang and Lulu Lv. Their combined expertise contributes to the ongoing research and development efforts at Juventas Cell Therapy Ltd.

Conclusion

Min Wang's contributions to the field of chimeric antigen receptors represent a significant advancement in cancer therapy. His innovative work continues to inspire new approaches in immunotherapy, showcasing the potential of targeted treatments in the fight against cancer.